Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors.
Beckermann KE, Bestvina CM, El Osta B, Sanborn RE, Borghaei H, Lammers PE, Selvaggi G, Whisenant JG, Heimann-Nichols E, Berry L, Hsu CY, Shyr Y, Horn L, Wakelee H. Beckermann KE, et al. Among authors: borghaei h. JTO Clin Res Rep. 2023 Dec 15;5(2):100619. doi: 10.1016/j.jtocrr.2023.100619. eCollection 2024 Feb. JTO Clin Res Rep. 2023. PMID: 38328473 Free PMC article.
Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.
Weiss J, Kavanagh B, Deal A, Villaruz L, Stevenson J, Camidge R, Borghaei H, West J, Kirpalani P, Morris D, Lee C, Pecot CV, Zagar T, Stinchcombe T, Pennell N. Weiss J, et al. Among authors: borghaei h. Cancer Treat Res Commun. 2019;19:100126. doi: 10.1016/j.ctarc.2019.100126. Epub 2019 Feb 26. Cancer Treat Res Commun. 2019. PMID: 30852467 Clinical Trial.
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
Huang CH, Millenson MM, Sherman EJ, Borghaei H, Mintzer DM, Cohen RB, Staddon AP, Seldomridge J, Treat OJ, Tuttle H, Ruth KJ, Langer CJ. Huang CH, et al. Among authors: borghaei h. J Thorac Oncol. 2008 Sep;3(9):1032-8. doi: 10.1097/JTO.0b013e31818307c2. J Thorac Oncol. 2008. PMID: 18758307 Free article. Clinical Trial.
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.
O'Brien S, Berman E, Borghaei H, Deangelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Pinilla-Ibarz J, Radich JP, Shah Md NP, Shami PJ, Smith BD, Snyder DS, Tallman MS, Talpaz M, Wetzler M; National Comprehensive Cancer Network. O'Brien S, et al. Among authors: borghaei h. J Natl Compr Canc Netw. 2009 Oct;7(9):984-1023. doi: 10.6004/jnccn.2009.0065. J Natl Compr Canc Netw. 2009. PMID: 19878641 No abstract available.
Mesothelin, a novel immunotherapy target for triple negative breast cancer.
Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vondeheide RH, Albelda SM, June CH, Zhang PJ. Tchou J, et al. Among authors: borghaei h. Breast Cancer Res Treat. 2012 Jun;133(2):799-804. doi: 10.1007/s10549-012-2018-4. Epub 2012 Mar 15. Breast Cancer Res Treat. 2012. PMID: 22418702 Free PMC article.
136 results